JP2005505604A - ホスホロジエステラーゼｉｖ阻害剤の使用 - Google Patents

ホスホロジエステラーゼｉｖ阻害剤の使用 Download PDF

Info

Publication number
JP2005505604A
JP2005505604A JP2003535796A JP2003535796A JP2005505604A JP 2005505604 A JP2005505604 A JP 2005505604A JP 2003535796 A JP2003535796 A JP 2003535796A JP 2003535796 A JP2003535796 A JP 2003535796A JP 2005505604 A JP2005505604 A JP 2005505604A
Authority
JP
Japan
Prior art keywords
ethyl
dihydro
tetrahydropyridazin
carbonylamino
thiadiazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505604A5 (enExample
Inventor
ハンス−ミハエル エゲンヴァイラー、
ミハエル ヴォルフ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7702358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005505604(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2005505604A publication Critical patent/JP2005505604A/ja
Publication of JP2005505604A5 publication Critical patent/JP2005505604A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003535796A 2001-10-12 2002-09-19 ホスホロジエステラーゼｉｖ阻害剤の使用 Pending JP2005505604A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10150517A DE10150517A1 (de) 2001-10-12 2001-10-12 Verwendung von Phosphodiesterase IV-Inhibitoren
PCT/EP2002/010507 WO2003032993A1 (de) 2001-10-12 2002-09-19 Verwendung von phosphodiesterase iv - inhibitoren

Publications (2)

Publication Number Publication Date
JP2005505604A true JP2005505604A (ja) 2005-02-24
JP2005505604A5 JP2005505604A5 (enExample) 2005-12-22

Family

ID=7702358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535796A Pending JP2005505604A (ja) 2001-10-12 2002-09-19 ホスホロジエステラーゼｉｖ阻害剤の使用

Country Status (15)

Country Link
US (1) US20040235845A1 (enExample)
EP (1) EP1435958A1 (enExample)
JP (1) JP2005505604A (enExample)
KR (1) KR20050028900A (enExample)
CN (1) CN1564687A (enExample)
AR (1) AR037741A1 (enExample)
AU (1) AU2002338734B2 (enExample)
CA (1) CA2460135C (enExample)
CZ (1) CZ2004457A3 (enExample)
DE (1) DE10150517A1 (enExample)
HU (1) HUP0401641A3 (enExample)
MX (1) MXPA04002639A (enExample)
NO (1) NO20041938L (enExample)
SK (1) SK1652004A3 (enExample)
WO (1) WO2003032993A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516658A (ja) * 2005-11-21 2009-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
JP2009516657A (ja) * 2005-11-21 2009-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 置換５−フェニル−３，６−ジヒドロ−２−オキソ−６ｈ−［１，３，４］チアジアジン

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
AU2005210042B2 (en) 2004-02-04 2011-04-21 Takeda Gmbh 2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
MX2007010560A (es) 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.
UA100497C2 (ru) 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
RU2626677C1 (ru) * 2016-03-09 2017-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение фармацевтической композиции 2-морфолино-5-фенил-6н-1,3,4-тиадиазина с аскорбиновой кислотой в качестве средства коррекции аллоксанового сахарного диабета
MA59016B1 (fr) * 2022-12-30 2024-09-30 Université Ibn Tofail Nouveaux composés hétérocycliques de type 1,3,4-thiadiazines pour le traitement du diabète de type 2

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222017A (ja) * 1991-10-23 1993-08-31 Merck Patent Gmbh チアジアジノン類
JPH072812A (ja) * 1993-04-01 1995-01-06 Merck Patent Gmbh チアジアジノン
JPH08231522A (ja) * 1995-01-28 1996-09-10 Merck Patent Gmbh アリールアルキル−チアジアジノン誘導体
JPH08291145A (ja) * 1995-04-20 1996-11-05 Merck Patent Gmbh アリールアルキルピリダジノン化合物
JPH09124611A (ja) * 1995-09-14 1997-05-13 Merck Patent Gmbh アリールアルキルジアジノン化合物
JPH09202785A (ja) * 1995-12-11 1997-08-05 Bayer Ag 複素環式カルボニルに置換されたベンゾフラニル尿素類
DE19604388A1 (de) * 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10503173A (ja) * 1994-06-21 1998-03-24 セルテック セラピュティクス リミテッド Ｐｄｅ ｉｖ インヒビターとして有用なトリ置換フェニル誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222017A (ja) * 1991-10-23 1993-08-31 Merck Patent Gmbh チアジアジノン類
JPH072812A (ja) * 1993-04-01 1995-01-06 Merck Patent Gmbh チアジアジノン
JPH10503173A (ja) * 1994-06-21 1998-03-24 セルテック セラピュティクス リミテッド Ｐｄｅ ｉｖ インヒビターとして有用なトリ置換フェニル誘導体
JPH08231522A (ja) * 1995-01-28 1996-09-10 Merck Patent Gmbh アリールアルキル−チアジアジノン誘導体
JPH08291145A (ja) * 1995-04-20 1996-11-05 Merck Patent Gmbh アリールアルキルピリダジノン化合物
JPH09124611A (ja) * 1995-09-14 1997-05-13 Merck Patent Gmbh アリールアルキルジアジノン化合物
JPH09202785A (ja) * 1995-12-11 1997-08-05 Bayer Ag 複素環式カルボニルに置換されたベンゾフラニル尿素類
DE19604388A1 (de) * 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5004001626, ＤＹＫＥ Ｈ Ｊ, ＥＸＰＥＲＴ ＯＰＩＮＩＯＮ ＯＮ ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ ＤＲＵＧＳ, 1999, Ｖ８ Ｎ９, Ｐ１３０１−１３２５, GB, ＡＳＨＬＥＹ ＰＵＢＬＩＣＡＴＩＯＮＳ ＬＴＤ． *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516658A (ja) * 2005-11-21 2009-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
JP2009516657A (ja) * 2005-11-21 2009-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 置換５−フェニル−３，６−ジヒドロ−２−オキソ−６ｈ−［１，３，４］チアジアジン

Also Published As

Publication number Publication date
SK1652004A3 (sk) 2005-05-05
HUP0401641A2 (hu) 2004-11-29
CA2460135C (en) 2010-08-24
MXPA04002639A (es) 2004-06-07
KR20050028900A (ko) 2005-03-23
US20040235845A1 (en) 2004-11-25
CA2460135A1 (en) 2003-04-24
EP1435958A1 (de) 2004-07-14
WO2003032993A1 (de) 2003-04-24
HUP0401641A3 (en) 2007-02-28
AU2002338734B2 (en) 2007-11-08
NO20041938L (no) 2004-05-11
CZ2004457A3 (cs) 2005-04-13
DE10150517A1 (de) 2003-04-17
AR037741A1 (es) 2004-12-01
CN1564687A (zh) 2005-01-12

Similar Documents

Publication Publication Date Title
JP2005505604A (ja) ホスホロジエステラーゼｉｖ阻害剤の使用
US20050085509A1 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
RU2269519C2 (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
JP2008537741A5 (enExample)
KR102316234B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP6728198B2 (ja) 置換トリアゾールおよびそれに関する方法
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
EP0369887B1 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
JPS6143176A (ja) ａ‐アリール‐４‐（４，５‐ジヒドロ‐３，５‐ジオキソ‐１，２，４‐トリアジン‐２（３Ｈ）‐イル）‐ベンゼンアセトニトリル
SK287362B6 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
US20060258713A1 (en) Treatment of pain
HU192975B (en) Process for preparing pyridazine derivatives with psychotropic activity
Kadaba Rational Drug Design and the Discovery of the Δ2-1, 2, 3-Triazolines, A Unique Class of Anticonvulsant and Antiischemic Agents
HUT77317A (hu) Indolszármazékok alkalmazása különböző betegségek kezelésére alkalmas gyógyszer előállítására
JPS6351328A (ja) 脳細胞保護作用を有する医薬組成物
CN1311677A (zh) 顽固性癫痫的治疗剂或预防剂
US4091221A (en) 3-(Benzoyl)oxiranecarboxamides
HU194847B (en) Process for producing 1-/acetyl-amino-phenyl/-2-amino-propanone derivatives and salts and pharmaceutical compositions containing them as active components
CA2659754A1 (fr) Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CA2066364C (en) Psychoactive propargylamine derivatives
WO2007026224A2 (en) 5-ht1b antagonist composition for depression, anxiety and cognition
JP4198755B2 (ja) アリールアルカノイルピリダジン誘導体
JP4198755B6 (ja) アリールアルカノイルピリダジン誘導体
MXPA01001326A (en) Remedies or preventives for intractable epilepsy
BE695133A (enExample)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100317

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100514

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100604

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100625